Abbott Laboratories heads into Q3 earnings season with a paradox: analysts are more bullish than they've been in years, yet the stock is down 11% over the past month and the CEO has been selling heavily at prices well above where shares now trade.
The most striking data point in recent weeks is the insider activity. CEO Robert Ford exercised options and sold shares in late August, netting roughly $46M in proceeds from open-market sales — $20.9M at $116.19 and $25.3M at $115.57 — while simultaneously exercising options at far lower strike prices. The open-market sales, not made under a pre-arranged 10b5-1 plan, came when the stock was trading meaningfully above its current level of $103.69. The VP and Controller also posted a small discretionary sale on September 2. With a 90-day insider net of -$46.9M across all transaction types, the insider register does not paint a picture of executives loading up on their own stock at the current price, though the bulk of that figure reflects Ford's compensation-linked exercises paired with same-day sales rather than pure conviction selling.
The positioning backdrop is, by contrast, almost entirely benign. Short interest in Abbott is negligible — just 1.26% of the free float — and has been drifting lower, falling roughly 3.4% over the past month. That is not a story worth dwelling on. Borrow conditions confirm the picture: availability is essentially uncapped, with the lending pool barely touched, and the cost to borrow has eased to 0.41% after briefly spiking toward mid-month. The ORTEX short score sits at 29.8, well below the midpoint, placing Abbott in the bottom quarter of the universe for short-selling pressure. Options are similarly unexcited: the put/call ratio at 0.63 is slightly above its 20-day average of 0.60, but the z-score of 0.65 points to no meaningful shift in hedging demand ahead of the October 14 print.
The Street, however, is firmly in the bull camp. The consensus rating is a buy, with 18 buy-side recommendations and a mean price target of $120.26 — implying roughly 16% upside from current levels. That gap reflects the 11% pullback, not analyst capitulation: the recent wave of analyst activity has been almost entirely constructive. TD Cowen reiterated Buy and lifted its target to $135 in mid-August. Wolfe Research upgraded to Outperform in August, setting a $130 target. Citigroup raised its target to $125. The one exception was UBS, which trimmed its target from $135 to $125 while keeping Buy, citing near-term uncertainty. On valuation, the P/E has compressed to 17.5x — down 2.3 points over the past month — while the price-to-book has eased to 3.6x. The EV/EBITDA of 13.2x is modestly above where the stock sat a month ago, but the re-rating is largely a price move rather than an estimate cut. The factor score picture supports the analyst lean: the analyst recommendation divergence score ranks in the 95th percentile, meaning analyst conviction is running unusually high relative to the rest of the universe. The dividend score at the 98th percentile reflects Abbott's long track record of capital returns.
Peers add context to the relative performance. MDT and RMD are both down more than 3% on the week. BDX and SYK fell between 1.6% and 2.3%. Against that, Abbott's 1.6% weekly gain looks like genuine relative resilience, and GEHC and COO — the week's outperformers in the peer group — are up 3.4% and 3.8% respectively, suggesting some rotation into healthcare equipment after the sector's bruising month.
The next major test is the Q3 print on October 14. Abbott's last two earnings releases each produced one-day moves of more than 11%, both to the upside — a pattern that helped drive the run to the $115–$116 level where Ford was selling in August. Whether the stock can recapture that ground depends on execution in the cardiovascular and diabetes device segments, where the bull case rests on TactiFlex Duo adoption and Volt 2.0 momentum, while the bear case points to nutrition pricing pressure and regulatory timing risk. The gap between the consensus target and the current price means the October print is less about whether Abbott is growing and more about whether the growth trajectory justifies reloading at a lower entry point.
See the live data behind this article on ORTEX.
Open ABT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
